Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Power v. State Laws: Compounders Want Clarity On Office Use

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA says traditional compounding pharmacies cannot produce office stock, but some states specifically allow the practice, and the International Academy of Compounding Pharmacists wants help from Congress.

You may also be interested in...



Drug Compounding Can't Be Justified By Price, FDA Says

Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.

Ophthotech Underscores Limitations Of Anti-VEGFs in Wet AMD

The biotech took aim at ophthalmic rival Regeneron with a panel of physicians who pointed out the short-term nature of and side-effects associated with anti-VEGFs. It also emphasized that doctors want several treatments with distinct mechanisms of action, rather than the co-formulations that Regeneron plans.

Compounding The Problem: Congress, FDA Argue Over Regulatory Responsibility

After the House and Senate question whether FDA needs more authority to regulate compounders like the New England Compounding Center, Sen. Lamar Alexander suggests clearly designating who has jurisdiction may be the answer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel